Citadel Advisors’s Aprea Therapeutics APRE Stock Holding History

Citadel Advisors’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,041	Closed	-$43.5K	–	12922
2025 Q4	$43.5K	Buy	+51,041	New	+$62.7K	﹤0.01%	12095
2025 Q2	–	Sell	-30,083	Closed	-$61.4K	–	12423
2025 Q1	$61.4K	Buy	+30,083	New	+$94.2K	﹤0.01%	12088
2023 Q1	–	Sell	-64	Closed	-$411	–	14668
2022 Q4	$411	Buy	+64	New	+$675	﹤0.01%	14664
2022 Q3	–	Sell	-944	Closed	-$16.8K	–	12543
2022 Q2	$14K	Sell	944 -2,910	-76%	-$67.1K	﹤0.01%	12509
2022 Q1	$143K	Sell	3,854 -4,309	-53%	-$177K	﹤0.01%	11903
2021 Q4	$469K	Buy	8,163 +2,066	+34%	+$183K	﹤0.01%	9858
2021 Q3	$623K	Buy	6,097 +4,666	+326%	+$424K	﹤0.01%	9335
2021 Q2	$140K	Buy	+1,431	New	+$132K	﹤0.01%	12565
2020 Q4	–	Sell	-3,704	Closed	-$1.78M	–	10873
2020 Q3	$1.78M	Sell	3,704 -11,743	-76%	-$6.57M	﹤0.01%	4925
2020 Q2	$12M	Sell	15,447 -615	-4%	-$404K	﹤0.01%	2021
2020 Q1	$11.2M	Buy	16,062 +611	+4%	+$448K	0.01%	1742
2019 Q4	$14.2M	Buy	+15,451	New	+$8.51M	0.01%	1837

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's APRE Position: Q1 2026 in Review

Citadel Advisors sold out of Aprea Therapeutics (APRE) in Q1 2026, closing a stake of 51,041 shares — an estimated $43.5K sold.

Citadel Advisors first reported a position in APRE in Q4 2019 and held it in 12 quarters. The position peaked at $14.2M in Q4 2019. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

Citadel Advisors reported no remaining Aprea Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 51,041 Aprea Therapeutics shares in Q1 2026, an estimated $43.5K.
Citadel Advisors first reported a position in Aprea Therapeutics in Q4 2019 and held it in 12 quarters.
Citadel Advisors's Aprea Therapeutics position peaked at $14.2M in Q4 2019.
22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.